Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | CAR-T as a frontline standard of care in ALL?

Stephan Grupp • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T

Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses whether CAR-T therapy can be a frontline standard of care and first-line therapy in acute lymphoblastic leukemia (ALL). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Stephan Grupp

1:33
Patient selection for CAR-T in ALL
Stephan Grupp • 2 Sep 2021
2:16
The latest research in ALL cellular therapy
Stephan Grupp • 2 Sep 2021
1:21
The future of treating pediatric ALL with CAR-T
Stephan Grupp • 2 Sep 2021
0:57
The importance of common language for CAR-T
Stephan Grupp • 18 Mar 2021

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals